2000年Perou等通过cDNA微阵列技术分析来 自42例乳腺癌患者的65份标本的基因表达特征,首次提出将乳腺癌分为4个类型:导管型、正常乳腺样型、人表皮生长因子受体—2过表达型和基底细胞样型乳腺癌(basal-1ike breast cancer,BLBC)。由于Her—2过表达型乳腺癌和BLBC 预后较差,Nielsen等认为有必要在临床上加以区分,于是...
1.Antibody-Drug Conjugates Targeting theHuman Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci. 2022;9: 847835. 2. Implementing antibody-drugconjugates (ADCs) in HER2-positive breast cancer: state of the art and futuredirections. Breast Cancer Res. 2021; 23: 84. 更多生物制...
This paper provides an in-depth review of lapatinib, a dual HER kinase inhibitor, as well as some insight into three HER family members, in breast cancer.doi:10.1007/s12156-008-0052-6Gerald M. Higa1. Mary Babb Randolph Cancer Center, School of Pharmacy, West Virginia University, Morgantown...
Xu B, Li W, Zhang Q, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020 Aug;182(3):68...
1My friend Mary was 1 breast cancer. Her husband, Jack, called to tell me she was in the 2 .I spent as much time with them as I 3 in the next couple of weeks. I held her hand and 4 her favorite poetry until she fell asleep. I helped where I could, 5 my most important contr...
1.Antibody-Drug Conjugates Targeting theHuman Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci. 2022;9: 847835. 2. Implementing antibody-drugconjugates (ADCs) in HER2-positive breast cancer: state of the art and futuredirections. Breast Cancer Res. 2021; 23: 84. ...
Sharon H Giordano , et al. Is breast cancer survival improving? [J]. Cancer. 2004;100:44-52. Jordyn Kreutzfeldt, et al. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res[J]. 2020 Apr 1;10(4):1045-1067. eCollection 2020. ...
1.Antibody-Drug Conjugates Targeting theHuman Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci. 2022;9: 847835. 2. Implementing antibody-drugconjugates (ADCs) in HER2-positive breast cancer: state of the art and futuredirections. Breast Cancer Res. 2021; 23: 84....
[1]"Clinical significance and therapeutic implications of HER-2-low expression in breast cancer."Journal of Cancer Research and Clinical Oncology,vol.146,no.11,2020. [2]"HER-2-low breast cancer:an evolving entity ...
1.Antibody-Drug Conjugates Targeting theHuman Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci. 2022;9: 847835. 2. Implementing antibody-drugconjugates (ADCs) in HER2-positive breast cancer: state of the art and futuredirections. Breast Cancer Res. 2021; 23: 84....